An α-Helix-Mimicking 12,13-Helix: Designed α/β/γ-Foldamers as Selective Inhibitors of Protein-Protein Interactions by Grison, CM et al.
Internationale Ausgabe: DOI: 10.1002/anie.201604517Peptidomimetics
Deutsche Ausgabe: DOI: 10.1002/ange.201604517
An a-Helix-Mimicking 12,13-Helix: Designed a/b/g-Foldamers as
Selective Inhibitors of Protein–Protein Interactions
Claire M. Grison, Jennifer A. Miles, Sylvie Robin, Andrew J. Wilson,* and David J. Aitken*
Abstract:Amajor current challenge in bioorganic chemistry is
the identification of effective mimics of protein secondary
structures that act as inhibitors of protein–protein interactions
(PPIs). In this work, trans-2-aminocyclobutanecarboxylic acid
(tACBC) was used as the key b-amino acid component in the
design of a/b/g-peptides to structurally mimic a native a-helix.
Suitably functionalized a/b/g-peptides assume an a-helix-
mimicking 12,13-helix conformation in solution, exhibit
enhanced proteolytic stability in comparison to the wild-type
a-peptide parent sequence fromwhich they are derived, and act
as selective inhibitors of the p53/hDM2 interaction.
Foldamers are unnatural oligomers that adopt well-defined
secondary and tertiary conformations.[1–4] As bioinspired
structures, some of them have been validated as useful
reagents to modulate (therapeutically important) biological
processes and systems,[4–9] and others as building blocks for
use in synthetic biology[10–14] or the construction of functional
materials.[15, 16] A particularly fertile area is centred on the
search for foldamers that mimic natural secondary structures
(specifically a-helices) and thereby act as inhibitors of
protein–protein interactions (PPIs).[17–21] However, there is
still a need to develop ligands that more effectively mimic the
conformation and molecular recognition capabilities of the a-
helix. Herein, we present the bottom-up design of hybrid a/b/
g-peptides that assume an a-helix-mimicking 12,13-helical
conformation and function as effective inhibitors of the p53/
hDM2 interaction.
Amongst a multitude of foldamer classes where struc-
tural/ conformational determinants have been mapped,[1–4] b-
peptides and hybrid a/b-peptides, in which b-amino acids are
dispersed along an a-peptide backbone, can inhibit a-helix-
mediated protein–protein interactions[22–29] and mimic the
structure and the function of protein surfaces.[30,31] Nonethe-
less foldamers that more accurately mimic the topology and
topography of the a-helix might prove advantageous in
comparison to b- and a/b-peptides, which may not fully mimic
the spatial presentation of a-helix side chains. Several
foldamer scaffolds have been hypothesized to have potential
for the inhibition of a-helix-mediated PPIs,[32–35] but they have
not yet been shown to do so experimentally. b/g-Peptide
sequences fall into this category: a dipeptide of b- and g-
residues forming a 13-membered hydrogen-bonded ring (C=
O(i)-NH(i+ 3)) is analogous to a tripeptide of a-amino acids
forming the 13-membered hydrogen-bonded ring (C=O(i)-
NH(i+ 4)) of the native a-helix. The 13-helix represents
a more accurate topographical mimic of the natural a(413)-
helix and represents an attractive template on which to
elaborate inhibitors of protein–protein interactions. Whilst
both the Gellman and Balaram groups have previously
demonstrated that the introduction of b and g residues is
tolerated within sequences of a-amino acids, which retain the
secondary structure of the a-helix,[36–38] the approach de-
scribed herein is quite distinct in that a novel-fold is designed
in a bottom-up manner to mimic the topology and side-chain
presentation of an a-helix.
We have recently demonstrated that an alternating
sequence of the b-amino acid trans-2-aminocyclobutanecar-
boxylic acid (tACBC) and g-amino acids can adopt a 9/8-
ribbon[39] or a robust 13-helix[40] in solution, depending on the
absence or presence of branching within the g-amino acid
monomer. We therefore examined the ability of b/g-peptide
manifolds to behave as a-helix mimetics by designing
mimetics of the N-terminal helical domain (residues 19–26)
of the transcription factor p53 (Figure 1). b/g-Peptide mim-
etics were designed to display three known hot-spot residues
of p53 at the correct positions: Phe (i), Trp (i+ 4), and Leu
(i+ 7). The primary sequence of p5319–26 and a b/g-peptide
backbone with alternating tACBC and g-amino acids were
aligned in order to map appropriately positioned side chains.
Although Ser20 from p53 appears to align well with the g-
residue at position 2 in the a/b/g-peptides, it is not a hot-spot
residue and hence for this first generation, g4-Ala was used in
this position to ensure that a helical conformation would be
promoted.[40] Two series of four a/b/g-hexapeptides (1–8 ;
Figure 1) were proposed: N-Boc-protected (1–4) and N-
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acetamide (5–8) peptides. Both series featured g4-Leu and
Leu at the C terminus, since only the amino acid side chain
was a prerequisite, as well as g4-Trp and g4-Phe, since previous
studies have shown that the replacement of indole with
phenyl in the Trp21-mimicking position does not necessarily
alter the affinity of peptidomimetics for hDM2.[18] Peptides 1–
8 were prepared by using standard solution-state methods
(see the Supporting Information), and conformational anal-
ysis was performed by using solution-state spectroscopic
techniques and molecular modelling.
The 1H NMR spectra of theN-Boc-protected peptides 1–4
in CDCl3 were well-defined and the signals were conveniently
dispersed, thus allowing complete residue assignment and
unambiguous attribution of all signals pertinent for conforma-
tional analysis by using standard 1D and 2D NMR sequences.
ROESY experiments revealed correlations between non-
adjacent residues (Figure 2a); similar ROE correlation
patterns were observed for all four N-Boc-protected a/b/g-
peptides. In b/g-segments, ROEs characteristic of 13-mem-
bered hydrogen-bonded rings were detected: Hb(i)-NH(i+
2), Hb(i)-Ha(i+ 2), Hg(i)-NH(i+ 2).[40] In N-terminal a/g/b-
segments, related ROEs were detected: Ha(i)-NH(i+ 2),
Ha(i)-Ha(i+ 2).[40] These latter correlations are indicative of
a 12-membered hydrogen-bonded ring in this segment of the
peptide, which was corroborated by the down-field chemical
shift values and the high [D6]DMSO titration coefficients
observed for the amide NH signals from Phe1 and g4-Ala2 in
the 1H NMR spectra (see the Supporting Information for
more details). These data fully support the proposal that the
a/b/g-peptides 1–4 predominantly adopt a well-defined folded
conformation containing one C12 and three C13 features
(Figure 2b), which we refer to as a 12,13-helix.
Solution-state IR absorption spectra of the N-Boc-pro-
tected peptides 1–4 recorded in CDCl3 (Figure 2c) further
support these conclusions. In all cases, in addition to a free
NH absorption (around 3425 cm@1), a strong, low-frequency
amide NH absorption band was observed (around 3325 cm@1),
as would be expected for 12- and 13-membered H-bonded
features. A free indole NH absorption band was also observed
(around 3480 cm@1) for peptides 1 and 2.
The lower solubility of peptides 5–8 in aprotic solvents
(< 1 mm in CDCl3) precluded similar NMR and IR studies for
these compounds. However, the far-UV CD spectra of all a/b/
g-peptides 1–8 were recorded in 0.2 mm MeOH solution and
each showed a marked Cotton effect, presenting a minimum
around 206 nm and a maximum around 224 nm (Figure 2d).
These data compare closely with the methanol-solution
signatures of both the 13-helix adopted by b/g-peptides and
the 12-helix adopted by b-peptides,[40–42] thus suggesting that
a/b/g-peptides 1–8 adopt a similar folded conformation in the
same solvent. Collectively, the NMR, IR, and CD data
provide strong evidence that a/b/g-peptides 1–8 are capable
of adopting a hydrogen-bonded helical conformation in
hydrogen-bonding and non-hydrogen-bonding solvents.
A hybrid Monte Carlo multiple minima (MCMM)
molecular mechanics conformational search[43] was carried
out on a/b/g-peptides using MacroModel 10.6 and the
MMFFs force field without restraints; in chloroform, octanol,
or water for peptides 1–4, and in octanol or water for peptides
5–8. The conformational landscapes were largely dominated
by a well-defined 12,13-helix (relative abundance > 67% in
chloroform, 100% in octanol) comprised of the C12 and C13
Figure 1. Alignment of key side chains. a) The p53(19—26) segment.
b) Structures of the a/b/g-peptide helix mimetics (1–8) studied in this
work.
Figure 2. Conformational analyses of peptides 1–8. a) Structures of N-
Boc-protected a/b/g-peptides 1–4, highlighting significant 1H NMR
data (10 mm in CDCl3): amide NH signals with high [D6]DMSO
titration coefficients (in green) and ROEs observed between non-
adjacent residues (blue arrows). b) The same structures of 1–4
showing the interpretation of the above data in terms of a 12,13-helix,
comprised of a succession of 12- and 13-membered hydrogen-bonded
rings (pink and red, respectively). c) IR absorption spectra (10 mm in
CDCl3) of N-Boc-protected a/b/g-peptides 1–4. d) CD spectra (0.2 mm
in MeOH) of a/b/g-peptides 1–8.
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features as deduced from the spectroscopic analyses. As we
anticipated, a solvent with a higher dielectric constant (water)
does not significantly change the conformational landscape of
the a/b/g-peptides; some fraying at the N-terminus is
observed, which reduces the population of 12,13- and 13-
helical conformers to the range 47–79%. However, the key
central residues are essentially locked in a 13-helical con-
formation (see the Supporting Information). Peptides 1–8
were subjected to ab initio geometry optimization by DFT
using Gaussian09 at the B3LYP/6-311G(d,p) level of theory.
The lowest-energy structures of 1–4 and 5–8 were super-
imposed (Figure 3a,b) and the backbone of peptide 2 (as
a representative example) was overlaid with the crystal
structure of p5316–29 (Figure 3c) using g
4-amino acid C(a)
atoms as the basis of the alignment. The superimposition gave
an excellent RMSD value of around 0.9c (Figure 3d,e), thus
strongly suggesting that the a/b/g-peptides 1–8 effectively
mimic an a-helix. Gratifyingly, selected side chains can be
accommodated in the required positions to mimic those of
a native a-peptide without affecting the ability to adopt
a helix, which suggests that a/b/g-peptides might have wider
use as a-helix-mimetic scaffolds.
The proteolytic stability of a/b/g-peptides 1–8 was inves-
tigated using a-chymotrypsin (a-CT) as a representative
protease, since this enzyme selectively hydrolyses the amide
bond on the C-terminal side of hydrophobic residues such as
Leu, Trp, and Phe, all of which are present in the a/b/g-
peptide sequences. The p5315–31 peptide was also studied for
comparison (see the Supporting Information). Using HPLC
to assess the progress of peptide digestion, it transpired that
all eight a/b/g-peptides displayed considerably greater resist-
ance to a-CT than did the native p5315–31 (+ 32-fold for 2, 4, 6,
and 8 and+ 10-fold for 1, 3, 5, and 7; Figure 4a). For the latter
four peptides, the proteolytic activity corresponded to methyl
ester hydrolysis of the C-terminal Leu residue; in all eight
cases, therefore, the hexapeptide core remained largely intact
for the duration of the experiments.
The ability of the a/b/g-peptides to act as functional
mimics of p53 was examined by using a fluorescence aniso-
tropy (FA)-based competition assay wherein the displace-
Figure 3. Molecular modelling of a/b/g-peptides. a) Superimposition
of the calculated lowest-energy conformers of a/b/g-peptides 1—4.
b) The same such structures of peptides 5—8. C yellow, N blue and O
red. c) Representation of the crystal structure of p5316–29 excised from
its complex with hDM2 (PDB ID: 1YCR) highlighting the helical back-
bone (in red) and the hot-spot side chains (in green). d) Overlays of
the backbones of a/b/g-peptide 2 (yellow backbone) and of p5316–29
peptide (red backbone); RMSD is 0.89 b for the a-carbons. e) Hot-
spot matching. Colors as for (c) and (d).
Figure 4. Biophysical analysis of the a/b/g-peptides. a) proteolytic
degradation of peptides 1–8 and p5315–31. b, c) Dose–response curves
for 1–4 (b) and 5–8 (c) in an FA competition assay against p53/hDM2
(50 nm of FITC–p53 and 150 nm of hDM2 in 40 mm phosphate buffer,
pH 7.5, 200 mm NaCl, 0.02 mgmL@1 BSA, 5% DMSO). d) 1H-15N
HSQC spectra of 15N-labelled hDM2 (87 mm in 100 mm sodium
phosphate buffer, pH 7.3, 2.5% glycerol, 1 mm DTT, 5% DMSO),
recorded in the absence (black) and the presence (red) of 200 mm 2
(left), with cross-peaks that move mapped onto the surface of hDM2
and shown in blue (right). BSA=bovine serum albumin, DMSO=di-
methyl sulfoxide, DTT=1,4-dithiothreitol.
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ment of fluorescein-labelled p53 (FITC–p5315–31) from the
binding groove of hDM2 is monitored upon titration with the
competitor peptide, with the objective of determining a half-
maximal inhibitory concentrating (IC50) value (Figure 4b,c).
Peptides 3, 4, 5, and 7 were found to bind to hDM2 but were
not sufficiently potent ligands to generate full competition
curves (IC50> 100 mm). Peptides 6 and 8 effectively displaced
FITC–p5315–31 at micromolar concentrations, although the
lower asymptote of the competition curve was not achieved
for higher concentrations. Peptides 1 and 2 generated full
competition curves with good potency: IC50 values were
calculated as 57: 22 mm for 1 and 15: 2 mm for 2. It is
noteworthy that the inhibitory potency of 1 and 2 for hDM2 is
only one order of magnitude lower than that of the native
sequence p5315–31 (IC50= 1.2: 0.1 mm) and that of nutlin,[44]
a well-known inhibitor of p53/hDM2 (IC50= 0.434:
0.024 mm), and is superior to that previously reported for
first-generation b-peptides.[27] The difference in behavior
between the peptide pair 1 and 2 and the peptide pair 3 and
4 indicates that g4-Trp plays a significant role in binding to
hDM2, as is indeed the case for Trp21 in the native p53
protein. Importantly, in further FA assays conducted for the
BODIPY–BAK/Bcl-xL and the FITC–NOXA B/Mcl-1 pro-
tein–protein interactions, peptides 1 and 2 displayed no
inhibitory activity, thus indicating that their binding to hDM2
is selective (see the Supporting Information).
Peptide 2 was assessed for its ability to bind to 15N-
labelled hDM2 at the native p53 protein binding cleft. Peptide
8 was also tested as a negative control for comparison
purposes. 1H-15NHSQC spectra were recorded in the absence
and presence of the designated peptides (Figure 4d for 2 ; see
the Supporting Information for 8). Upon addition of 2, cross-
peaks in the 1H-15N HSQC spectrum shifted throughout the
protein, thus indicating a direct interaction with hDM2,
whereas no significant shifts were observed upon addition of
8. The chemical shifts were mapped onto the structure of
hDM2 by using a published NMR assignment.[45] The shift
changes were comparable to those induced by p5315–29 peptide
in its interaction with hDM2.[17,45, 46] Significant diagnostic
changes, characterized by strong peak shifts, were observed
for the amide NH of Phe55 and His73, which are located at
opposite edges of the hydrophobic cleft. This supports the
hypothesis that 2 binds to hDM2 in the canonical p53 binding
site.
In conclusion, a/b/g-peptides constructed from tACBC
and g4-amino acids are able to fold into 12,13-helices to
effectively mimic the a-helix. A demonstrated advantage of
the a/b/g-peptide motif compared to native a-peptides is
resistance to proteolytic degradation. Moreover, the results of
the FA assays establish for the first time that a/b/g-peptides
can act as functional and selective a-helix-mimetic inhibitors
of the p53/hDM2 interaction. The current design rationale has
focused on accurately reproducing the spatial presentation of
the three key p53 hot-spot residues (Phe-Trp-Leu); we
anticipate that further optimization studies might increase
the potency of these promising a/b/g-peptide scaffolds
through the incorporation of additional side chains other
than the key triad and by using affinity-improvement design
features identified in previous work.[47–49] Moreover, subse-
quent studies will focus on the use of these foldamer
manifolds for the programmable bottom-up design of mim-
etics of the native a-helix to target other PPIs.
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